Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2009

View Archived Issues

Capsaicin does not impair neurologic function in postherpetic neuralgia patients

Meta-analysis data suggest possible effectiveness of levetiracetam in status epilepticus

Abbott describes novel cannabinoid CB2 receptor ligands as analgesics

Analyses point to efficacy of telmisartan/amlodipine combination in hypertension

Better blood pressure profile seen with naproxcinod than with naproxen in osteoarthritis patients

Analgesic efficacy seen with tanezumab in chronic low back pain patients

Intraocular polymer implant may improve visual acuity in AMD; preliminary phase II data presented

Vertex presents new voltage-gated sodium channel inhibitors with analgesic activity

Vernalis and Servier sign new three-year joint oncology collaboration

HGS and Novozymes amend license agreement for albumin fusion technology

Sirius and Vanderbilt University sign collaborative agreement for VALID study

Axelar reports preliminary results from phase I/II clinical trial of AXL-1717

Burzynski Research reports positive results from phase II trial of ANP therapy in OPG

Nycomed submits MAA to EMEA for PDE4 enzyme inhibitor Daxas in COPD

Pharmacopeia patent discloses Janus kinase 3 inhibitors as immmunosupressants

Novel histamine H1 receptor antagonists described by GSK as antiinflammatory agents

Gilead Sciences offers Q1 pipeline update

Actelion receives DSMB recommendation to continue with BUILD-3 study in IPF

AdventRx reports results from ANX-514 bioequivalence study

The FDA approves Cetraxal for external otitis

FDA accepts Acorda's NDA for fampridine for improving walking ability in people with MS

Isotechnika enters into strategic collaboration and financing agreement with Paladin

Maxygen and Cangene sign licensing agreement for MAXY-G34 in ARS

Exelixis and Boehringer to develop S1P1 agonists for autoimmune diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...